<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21408161</article-id><article-id pub-id-type="pmc">3050888</article-id><article-id pub-id-type="publisher-id">PONE-D-10-03785</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0017366</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology</subject><subj-group><subject>Immunology</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Clinical Immunology</subject><subj-group><subject>Autoimmune Diseases</subject></subj-group></subj-group><subj-group><subject>Clinical Research Design</subject><subj-group><subject>Clinical Trials</subject></subj-group></subj-group><subj-group><subject>Gastroenterology and Hepatology</subject><subj-group><subject>Celiac Disease</subject><subject>Small Intestine</subject></subj-group></subj-group><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Parasitic Diseases</subject><subj-group><subject>Helminth Infection</subject><subject>Hookworm Infection</subject><subject>Hookworm</subject><subject>Soil-Transmitted Helminths</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Effect of Hookworm Infection on Wheat Challenge in Celiac Disease
&#x02013; A Randomised Double-Blinded Placebo Controlled Trial</article-title><alt-title alt-title-type="running-head">Trialling Hookworms in Celiac
Disease</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Daveson</surname><given-names>A. James</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Jones</surname><given-names>Dianne M.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Gaze</surname><given-names>Soraya</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>McSorley</surname><given-names>Henry</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Clouston</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Pascoe</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Cooke</surname><given-names>Sharon</given-names></name><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Speare</surname><given-names>Richard</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Macdonald</surname><given-names>Graeme A.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Anderson</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>McCarthy</surname><given-names>James S.</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Loukas</surname><given-names>Alex</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Croese</surname><given-names>John</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>&#x0002a;</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Princess Alexandra Hospital, Brisbane,
Australia</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>Queensland Institute of Medical Research,
Brisbane, Australia</addr-line>
</aff><aff id="aff3">
<label>3</label>
<addr-line>James Cook University, Townsville,
Australia</addr-line>
</aff><aff id="aff4">
<label>4</label>
<addr-line>Envoi Specialist Pathologists, Brisbane,
Australia</addr-line>
</aff><aff id="aff5">
<label>5</label>
<addr-line>The Townsville Hospital, Townsville,
Australia</addr-line>
</aff><aff id="aff6">
<label>6</label>
<addr-line>Walter and Eliza Hall Institute, Melbourne,
Australia</addr-line>
</aff><aff id="aff7">
<label>7</label>
<addr-line>University of Queensland, Brisbane,
Australia</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Gluud</surname><given-names>Lise Lotte</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Copenhagen University Hospital Gentofte, Denmark</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>jcroese@bigpond.com</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: JC AL JM. Performed the experiments:
JD DJ SG HM AC AP SC RS JM. Analyzed the data: JD DJ SG HM AC RS RA JM AL
JC. Wrote the manuscript: JD DJ SG HM RS RA JM AL JC. Clinical site study
supervision: GM.</p></fn></author-notes><pub-date pub-type="collection"><year>2011</year></pub-date><pub-date pub-type="epub"><day>8</day><month>3</month><year>2011</year></pub-date><volume>6</volume><issue>3</issue><elocation-id>e17366</elocation-id><history><date date-type="received"><day>1</day><month>10</month><year>2010</year></date><date date-type="accepted"><day>31</day><month>1</month><year>2011</year></date></history><permissions><copyright-statement>Daveson et al.</copyright-statement><copyright-year>2011</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><sec><title>Background and Aims</title><p>The association between hygiene and prevalence of autoimmune disease has been
attributed in part to enteric helminth infection. A pilot study of
experimental infection with the hookworm <italic>Necator americanus</italic>
was undertaken among a group of otherwise healthy people with celiac disease
to test the potential of the helminth to suppress the immunopathology
induced by gluten.</p></sec><sec><title>Methods</title><p>In a 21-week, double-blinded, placebo-controlled study, we explored the
effects of <italic>N. americanus</italic> infection in 20 healthy,
helminth-na&#x000ef;ve adults with celiac disease well controlled by diet.
Staged cutaneous inoculations with 10 and 5 infective 3<sup>rd</sup> stage
hookworm larvae or placebo were performed at week-0 and -12 respectively. At
week-20, a five day oral wheat challenge equivalent to 16 grams of gluten
per day was undertaken. Primary outcomes included duodenal Marsh score and
quantification of the immunodominant &#x003b1;-gliadin peptide (QE65)-specific
systemic interferon-&#x003b3;-producing cells by ELISpot pre- and post-wheat
challenge.</p></sec><sec><title>Results</title><p>Enteric colonisation with hookworm established in all 10 cases, resulting in
transiently painful enteritis in 5. Chronic infection was asymptomatic, with
no effect on hemoglobin levels. Although some duodenal eosinophilia was
apparent, hookworm-infected mucosa retained a healthy appearance. In both
groups, wheat challenge caused deterioration in both primary and several
secondary outcomes.</p></sec><sec><title>Conclusions</title><p>Experimental <italic>N. americanus</italic> infection proved to be safe and
enabled testing its effect on a range of measures of the human autoimmune
response. Infection imposed no obvious benefit on pathology.</p></sec><sec><title>Trial Registration</title><p>ClinicalTrials.gov <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/ct2/show/NCT00671138">NCT00671138</ext-link>
</p></sec></abstract><counts><page-count count="9"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>The &#x0201c;hygiene hypothesis&#x0201d; proposes that the increasing prevalence of
allergic and autoimmune diseases in developed countries may be due to the reduction
in the incidence of infectious diseases <xref rid="pone.0017366-Bach1" ref-type="bibr">[1]</xref>; epidemiologic and genetic studies
suggest that the decline in the prevalence of helminth infections is a major factor
<xref rid="pone.0017366-Weinstock1" ref-type="bibr">[2]</xref>&#x02013;<xref rid="pone.0017366-Fumagalli1" ref-type="bibr">[5]</xref>. Observational studies supporting this hypothesis include
a report that infection with the nematode <italic>Strongyloides stercoralis</italic>
is associated with protection against autoimmune liver disease <xref rid="pone.0017366-Aoyama1" ref-type="bibr">[6]</xref>, and another showing that
unspecified helminth infections with peripheral eosinophilia are associated with
reduced autoantigen-specific responses and disease progression in multiple sclerosis
<xref rid="pone.0017366-Correale1" ref-type="bibr">[7]</xref>.
Co-infection with helminths is also known to attenuate murine models of autoimmunity
and inflammatory bowel disease <xref rid="pone.0017366-Elliott1" ref-type="bibr">[8]</xref>, <xref rid="pone.0017366-Ruyssers1" ref-type="bibr">[9]</xref>.</p><p>Despite being classed as pathogens <xref rid="pone.0017366-Musgrove1" ref-type="bibr">[10]</xref>, helminth parasites are being proposed as treatments for
allergic and autoimmune diseases <xref rid="pone.0017366-Feary1" ref-type="bibr">[11]</xref>, <xref rid="pone.0017366-Bager1" ref-type="bibr">[12]</xref>. Preliminary observations suggest that intentional
infection with the zoophilic <italic>Trichuris suis</italic> is safe <xref rid="pone.0017366-Summers1" ref-type="bibr">[13]</xref>, and reduces
the activity of inflammatory bowel disease <xref rid="pone.0017366-Summers1" ref-type="bibr">[13]</xref>, <xref rid="pone.0017366-Summers2" ref-type="bibr">[14]</xref>. However, dosing with
<italic>T. suis</italic> every three weeks is required to maintain ongoing
infection because the human host does not sustain development of <italic>T.
suis</italic> to maturity <xref rid="pone.0017366-Summers2" ref-type="bibr">[14]</xref>.</p><p>
<italic>Necator americanus</italic> (NA) is a long-lived hematophagous,
human-specific (anthropophilic) gastrointestinal nematode that infects over 500
million people in developing countries where heavy infection causes iron deficiency
anemia, and is associated with reduced physical and intellectual development <xref rid="pone.0017366-Hotez1" ref-type="bibr">[15]</xref>. Experimental
infection of healthy volunteers with NA infective third-stage larvae (L<sub>3</sub>)
may cause an acute, painful enteropathy <xref rid="pone.0017366-Maxwell1" ref-type="bibr">[16]</xref>&#x02013;<xref rid="pone.0017366-Croese1" ref-type="bibr">[18]</xref>. Recent published data indicate
that low-dose inocula of NA are better tolerated <xref rid="pone.0017366-Mortimer1" ref-type="bibr">[19]</xref>, and because they do not
proliferate in humans, a defined dose can be administered and later fully eliminated
with anthelmintic therapy <xref rid="pone.0017366-Mortimer1" ref-type="bibr">[19]</xref>. A further advantage is infected individuals pose no risk
to others because hookworms are soil-transmitted (geohelminths) and cannot be
propagated in modern sanitary environments.</p><p>We chose NA and celiac disease (CD) to explore the relationship between helminth
infection and intestinal inflammation due to a well characterised dietary antigen,
gluten. Our previous studies with this hookworm have provided us with a pure source
of infective larvae <xref rid="pone.0017366-Croese1" ref-type="bibr">[18]</xref>, <xref rid="pone.0017366-Croese2" ref-type="bibr">[20]</xref>. Individuals carrying chronic infection with hookworms in
endemic settings demonstrate parasite-specific TH2 responses, but TH1 and TH2 immune
responses to other antigens are diminished <xref rid="pone.0017366-Quinnell1" ref-type="bibr">[21]</xref>.</p><p>Celiac disease is uniquely suited to explore the effects of helminth infection; it is
common <xref rid="pone.0017366-Leffler1" ref-type="bibr">[22]</xref> and
remission is achieved with elimination of dietary gluten allowing host-parasite
interaction to be studied free of potential artefacts caused by medications.
Clinical studies in volunteers with CD also have the advantage that the effects of
deliberate gluten exposure can be measured by symptom response, in blood and
intestinal tissue <xref rid="pone.0017366-Green1" ref-type="bibr">[23]</xref>&#x02013;<xref rid="pone.0017366-TyeDin1" ref-type="bibr">[26]</xref>. Over 90&#x00025; of people with CD possess genes encoding
the major histocompatability (MHC) Class II molecule, HLA-DQ2, and HLA
DQ2-restricted CD4<sup>&#x0002b;</sup> T cells specific for deamidated gluten peptides
can be isolated from intestinal tissue <xref rid="pone.0017366-TyeDin1" ref-type="bibr">[26]</xref>. HLA DQ2-restricted
CD4<sup>&#x0002b;</sup> TH1 cells specific for deamidated gluten including the
immunodominant &#x003b1;-gliadin 17-mer p57-73 (QE65) peptide are also present in blood
after oral wheat challenge <xref rid="pone.0017366-Anderson1" ref-type="bibr">[27]</xref>.</p><p>In this study, we undertook a clinical trial to test whether NA infection reduces the
immunotoxic effects of gluten in CD.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><p>The protocol for this trial and supporting CONSORT checklist are available as
supporting information; see <xref ref-type="supplementary-material" rid="pone.0017366.s001">Checklist S1</xref> and <xref ref-type="supplementary-material" rid="pone.0017366.s002">Protocol
S1</xref>.</p><sec id="s2a"><title>Ethics Statement</title><p>The Princess Alexandra Hospital, Queensland Institute of Medical Research and
Townsville Hospital Human Research Ethics Committees approved the study. Written
informed consent was obtained from all subjects.</p></sec><sec id="s2b"><title>Patients</title><p>Healthy people with CD aged 18 years or older were invited to participate through
the Queensland Coeliac Society. Inclusion criteria included: 1) pre-treatment
histological diagnosis of Marsh grade 3 celiac disease <xref rid="pone.0017366-Marsh1" ref-type="bibr">[25]</xref>, 2) positive immunoglobulin
(Ig) A anti-tissue transglutaminase (tTG) or anti-endomysial antibody, 3)
HLA-DQ2 phenotype, and 4) adherence to a gluten-free diet (GFD) for at least 6
months pre-enrolment <xref rid="pone.0017366-Kagnoff1" ref-type="bibr">[28]</xref>. Subjects were excluded if they had 1) insulin
dependent diabetes mellitus or Addison's disease; 2) life threatening
allergy; 3) treatment with immunomodulatory therapies within the six months
prior to enrolment (including aspirin, non-steroidal anti-inflammatory drugs,
celocoxib inhibitors, statins or intramuscular and intravenous steroids); 4) an
unmanaged risk of pregnancy; 5) historical, fecal or serological evidence of a
prior helminth infection; 6) iron deficiency anemia, 7) any vaccination within
the 30-day period prior to study commencement, or 8) an elevated level of tTG
IgA.</p></sec><sec id="s2c"><title>Study Design</title><p>This was a prospective, randomized, double-blinded, placebo-controlled trial
evaluating the safety, tolerability and immunological effects of NA infection in
subjects with CD in remission on gluten free diet and during wheat challenge.
Participants were matched by age and gender (<xref ref-type="table" rid="pone-0017366-t001">Table 1</xref>). Using a random number generation
sequence, the researcher preparing inocula independently of the clinical
support, assigned participants to the &#x0201c;hookworm&#x0201d; and
&#x0201c;control&#x0201d; groups. Primary end-points included duodenal histology
Marsh scores and systemic interferon-&#x003b3; measured by QE65-ELISpot pre- and
post-wheat challenge. Secondary end-points included a) the clinical response to
inoculation with hookworm, and b) subsequent response to the <italic>in
vivo</italic> wheat challenge, as measured by symptom and laboratory
indices, intraepithelial duodenal CD4<sup>&#x0002b;</sup>, CD8<sup>&#x0002b;</sup> and
CD3<sup>&#x0002b;</sup> lymphocyte counts (IEL), and duodenal villus
height/crypt depth (Vh/Cd) ratios. Because this was a Phase 1b/2a clinical trial
assessing safety, the hookworm and control sample sizes were deliberately
limited to ten volunteers each. Subjects and investigators remained blinded
throughout the trial.</p><table-wrap id="pone-0017366-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0017366.t001</object-id><label>Table 1</label><caption><title>Participant demographics.</title></caption><alternatives><graphic id="pone-0017366-t001-1" xlink:href="pone.0017366.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Control Subjects (n&#x0200a;=&#x0200a;10)</td><td align="left" rowspan="1" colspan="1">Hookworm Subjects
(n&#x0200a;=&#x0200a;10)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)<xref ref-type="table-fn" rid="nt101">1</xref>
<sup>,</sup>
<xref ref-type="table-fn" rid="nt102">2</xref>
</td><td align="left" rowspan="1" colspan="1">44 (25&#x02013;58)</td><td align="left" rowspan="1" colspan="1">47 (25&#x02013;62)</td></tr><tr><td align="left" rowspan="1" colspan="1">Gender (M/F)</td><td align="left" rowspan="1" colspan="1">2/8</td><td align="left" rowspan="1" colspan="1">2/8</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)<xref ref-type="table-fn" rid="nt103">3</xref>
<sup>,</sup>
<xref ref-type="table-fn" rid="nt102">2</xref>
</td><td align="left" rowspan="1" colspan="1">27 (22&#x02013;32)</td><td align="left" rowspan="1" colspan="1">26 (18&#x02013;31)</td></tr><tr><td align="left" rowspan="1" colspan="1">IgA tTG3 (U/ml)<xref ref-type="table-fn" rid="nt104">4</xref>
<sup>,</sup>
<xref ref-type="table-fn" rid="nt102">2</xref>
</td><td align="left" rowspan="1" colspan="1">9 (5&#x02013;15)</td><td align="left" rowspan="1" colspan="1">8 (5&#x02013;19)</td></tr><tr><td align="left" rowspan="1" colspan="1">Duration (months)<xref ref-type="table-fn" rid="nt105">5</xref>
<sup>,</sup>
<xref ref-type="table-fn" rid="nt102">2</xref>
</td><td align="left" rowspan="1" colspan="1">70 (10&#x02013;325)</td><td align="left" rowspan="1" colspan="1">77 (15&#x02013;143</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label>1</label><p>Age at enrolment,</p></fn><fn id="nt102"><label>2</label><p>mean value (range),</p></fn><fn id="nt103"><label>3</label><p>Body Mass Index,</p></fn><fn id="nt104"><label>4</label><p>Pre-enrolment IgA anti-tissue transglutaminase (normal range below 20
U/ml),</p></fn><fn id="nt105"><label>5</label><p>duration of gluten free diet.</p></fn></table-wrap-foot></table-wrap><sec id="s2c1"><title>Inocula and inoculation</title><p>Inoculations were performed at wk 0 (either 10 L<sub>3</sub> or placebo) and
wk 12 (either 5 L<sub>3</sub> or placebo). Inocula of five or ten NA
L<sub>3</sub> were prepared as previously described <xref rid="pone.0017366-Croese1" ref-type="bibr">[18]</xref>.
Placebo consisted of an identically presented inoculum containing 0.2 ml
McIlhenny Co Tabasco Pepper Sauce&#x000ae; to mimic the pruritus that
accompanies skin penetration by L<sub>3</sub>. A control sample of
L<sub>3</sub> was submitted with every batch of inoculum including
placebo, and was inspected microscopically for larval motility to verify
viability. All vials and pipettes were examined following inoculation to
ensure that there were no residual hookworm larvae. Evidence of hookworm
infection was provided by peripheral blood eosinophil count
(&#x000d7;10<sup>9</sup>/L), and documenting hookworm eggs in feces by
microscopy and/or by sighting a hookworm at endoscopy.</p><p>A strict GFD was maintained from weeks 0 to 20. Endoscopy was performed at
week 20 using an Olympus high resolution digital endoscope; five single-bite
biopsies were collected from the third part of the duodenum (D3), and seven
from the second part (D2). Volunteers consumed two 50 g slices of white
bread twice a day (equivalent to 16 g of gluten daily) for five days. On the
sixth day, blood was collected and a second endoscopy was performed
(referred to as the week 21 timepoint).</p></sec><sec id="s2c2"><title>Monitoring, assessments and wheat challenge</title><p>Clinical reviews occurred at weeks 0, 4, 12, 20 and 21, and symptom diaries
were recorded weekly. From weeks 0&#x02013;20 and daily during the wheat
challenge, participants were asked to complete a symptom score rating from 0
(none) to 3 (severe) bloating, constipation, flatulence, headaches,
lethargy, mouth ulcers, nausea, skin rash, skin itch, and vomiting, and to
record their number of bowel motions, loose bowel motions and urgent bowel
motions, and the number of episodes of pain per day. Also recorded were pain
intensity and general wellbeing on a visual analogue scale from &#x0201c;no
pain at all&#x0201d; to &#x0201c;very severe&#x0201d; and &#x0201c;very well&#x0201d;
to &#x0201c;severely ill&#x0201d; respectively.</p></sec></sec><sec id="s2d"><title>Histopathological Analysis</title><p>Biopsies were fixed in neutral buffered formalin, processed and carefully
orientated and embedded in paraffin wax. Sections (3 &#x000b5;m) were stained with
hematoxylin and eosin (H&#x00026;E) and immunostained with anti-CD8, anti-CD4 and
anti-CD3 antibodies (all from Novocastra Laboratories Ltd). The Marsh scores
were graded by two independent researchers <xref rid="pone.0017366-Marsh1" ref-type="bibr">[25]</xref>. The IELs per 100 nucleated
enterocytes (100NE) were counted at 24 randomly selected sites between the
villus tip to the base of the crypt in each biopsy. The Vh/Cd ratios were
measured independently of the Marsh grading <xref rid="pone.0017366-Catassi1" ref-type="bibr">[24]</xref> and were performed on 10
randomly selected well-orientated sites.</p></sec><sec id="s2e"><title>Peripheral blood interferon-&#x003b3; ELISpot responses to the immunodominant
&#x003b1;-gliadin peptide p57&#x02013;73 QE65</title><p>Peripheral blood mononuclear cells (PBMCs) were incubated with p57&#x02013;73 QE65
(50 &#x000b5;g/ml) in overnight IFN-&#x003b3; ELISpot assays, as previously described
<xref rid="pone.0017366-Anderson1" ref-type="bibr">[27]</xref>.
Briefly, ELISpot plates were coated with anti-IFN-&#x003b3; (clone 1-D1K, Mabtech)
and then blocked with 5&#x00025; fetal calf serum (FCS). Freshly isolated PBMCs
were added to wells containing medium alone (RPMI 1640, Invitrogen, 10&#x00025;
fetal bovine serum, 100 U/&#x000b5;l penicillin, 100 &#x000b5;g/ml streptomycin and
2 mM L-glutamine) or p57&#x02013;73 QE65 in medium, and cultured for 24 h at
37&#x000b0;C in 5&#x00025; CO<sub>2</sub>. Cells were removed and the plates were
incubated with anti-IFN-&#x003b3;-biotin (clone 7-B6-1, Mabtech), then
streptavidin-alkaline phosphatase, and developed with BCIP/NBT substrate. Spots
were counted on an iSpot ELISpot reader (Autoimmun Diagnostika GmbH).</p></sec><sec id="s2f"><title>Statistical Analyses</title><p>Statistical analyses were performed using Prism5 (GraphPad). When comparing
non-continuous variables (eg. symptom scores), area under the curve analysis
from week 1 to week 20 followed by Mann-Whitney U test was used to compare
between groups. For continuous variables (eg. duodenal IEL counts), two-way
ANOVA was used to analyse between time-points and groups. In the figures,
&#x0002a;&#x0200a;=&#x0200a;p&#x0003c;0.05,
&#x0002a;&#x0002a;&#x0200a;=&#x0200a;p&#x0003c;0.01,
&#x0002a;&#x0002a;&#x0002a;&#x0200a;=&#x0200a;p&#x0003c;0.001.</p></sec></sec><sec id="s3"><title>Results</title><p>Between October 2007 and March 2008, 131 potential subjects indicated interest, 61
were screened and twenty were enrolled and completed the study without protocol
violations (<xref ref-type="fig" rid="pone-0017366-g001">Figure 1</xref>). Reasons
for exclusion of subjects are summarised in <xref ref-type="fig" rid="pone-0017366-g002">Figure 2</xref>.</p><fig id="pone-0017366-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0017366.g001</object-id><label>Figure 1</label><caption><title>CONSORT flowchart.</title></caption><graphic xlink:href="pone.0017366.g001"/></fig><fig id="pone-0017366-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0017366.g002</object-id><label>Figure 2</label><caption><title>Recruitment and Protocol.</title><p>Recruitment and summation of those excluded post screening (A), and trial
outline (B).</p></caption><graphic xlink:href="pone.0017366.g002"/></fig><sec id="s3a"><title>Hookworm Tolerance and Safety</title><sec id="s3a1"><title>Inoculation efficacy</title><p>Mature hookworm infection was confirmed in each of the hookworm group by the
identification of eggs in feces (n&#x0200a;=&#x0200a;5), or by
endoscopic visualisation of at least one adult worm
(n&#x0200a;=&#x0200a;8; <xref ref-type="fig" rid="pone-0017366-g003">Figure 3A</xref>), or by both (n&#x0200a;=&#x0200a;3). In five
subjects with proven infection, patency could not be confirmed by fecal
microscopy despite the testing of 17 of 18 scheduled collections from wk
12&#x02013;21. No control subject had evidence of hookworm infection and no
subject had evidence of any other helminth infection.</p><fig id="pone-0017366-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0017366.g003</object-id><label>Figure 3</label><caption><title>Representative photographs of parasitic infection (A) Adult
hookworm (B) Inoculation site.</title></caption><graphic xlink:href="pone.0017366.g003"/></fig></sec><sec id="s3a2"><title>Clinical response to <italic>N. americanus</italic>
</title><p>
<italic>Symptom scores:</italic> No serious adverse event relating to
hookworm infection occurred. All subjects in the hookworm group developed
multiple tiny papules shortly after the application of L<sub>3</sub> (<xref ref-type="fig" rid="pone-0017366-g003">Figure 3B</xref>). Symptoms were
scored by questionnaire over the 20 weeks of hookworm infection (<xref ref-type="fig" rid="pone-0017366-g004">Figure 4A&#x02013;F</xref>). The
hookworm group experienced pain during the initial colonisation of the
intestine, but this resolved completely by week 16 (<xref ref-type="fig" rid="pone-0017366-g004">Figure 4A</xref>). There were trends towards the
hookworm group having less frequent bowel actions after colonisation was
established (<xref ref-type="fig" rid="pone-0017366-g004">Figure 4B</xref>),
and more flatulence (<xref ref-type="fig" rid="pone-0017366-g004">4C</xref>), nausea and bloating (data not shown) at earlier timepoints. The
inoculation site remained itchy until week 4 (<xref ref-type="fig" rid="pone-0017366-g004">Figure 4D</xref>). Unexpectedly, the hookworm
group experienced less lethargy than the controls (<xref ref-type="fig" rid="pone-0017366-g004">Figure 4E</xref>), and wellbeing was unaffected
(<xref ref-type="fig" rid="pone-0017366-g004">Figure 4F</xref>). At week
21, 5 of 10 subjects in the control group incorrectly guessed that they were
in the active hookworm-infected group, while 8 of the 10 in the hookworm
group confidently and correctly identified his or her infection status. At
the end of the study all infected subjects were offered anthelminthic
treatment but declined.</p><fig id="pone-0017366-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0017366.g004</object-id><label>Figure 4</label><caption><title>Symptom responses to hookworm infection.</title><p>Control group is indicated by black circles, hookworm group by grey
squares, values are mean &#x0002b;/&#x02212; SEM. (A) pain events, (B)
bowel motions/day, (C) flatulence, (D) skin rash, (E) lethargy, (F)
wellbeing. Area under the curve analysis followed by Mann-Whitney U
test to compare between groups showed that pain events (A) was
significantly different between the groups.</p></caption><graphic xlink:href="pone.0017366.g004"/></fig><p>
<italic>Laboratory Indices:</italic> A modest leukocytosis with an
eosinophilia was noticeable from week 4 after hookworm inoculation (<xref ref-type="fig" rid="pone-0017366-g005">Figure 5A&#x02013;B</xref>).
Hemoglobin levels were stable from week 0 to 20, but dropped at week 21 in
both groups after wheat challenge (<xref ref-type="fig" rid="pone-0017366-g005">Figure 5C</xref>).</p><fig id="pone-0017366-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0017366.g005</object-id><label>Figure 5</label><caption><title>Blood cell and marker levels.</title><p>(A) white cell, (B) eosinophil (C) hemoglobin. Control group is
indicated by black circles, hookworm group by grey squares, values
are mean &#x0002b;/&#x02212; SEM. Data was analyzed by two-way ANOVA:
significant effects of time and interaction was shown in (B), and
post-hoc one-way ANOVA on each group showed the differences between
timepoints as indicated.</p></caption><graphic xlink:href="pone.0017366.g005"/></fig></sec></sec><sec id="s3b"><title>Oral wheat challenge</title><sec id="s3b1"><title>Primary outcomes</title><p>
<italic>Mucosal damage measured by Marsh score:</italic> In both the hookworm
and control groups, mucosal damage deteriorated after the 5-day wheat
challenge (<xref ref-type="fig" rid="pone-0017366-g006">Figure 6A</xref>).
Although this deterioration was pronounced in the control group
(p&#x0200a;=&#x0200a;0.02), there was no statistical difference in
Marsh score between hookworm and control groups.</p><fig id="pone-0017366-g006" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0017366.g006</object-id><label>Figure 6</label><caption><title>Histological and immunological results.</title><p>(A) Marsh score and (B) IFN-&#x003b3; ELISpot. Data was analyzed by
two-way ANOVA: significant effects of time only were shown as
indicated, no significant effect of group or interaction was found
in (A) or (B).</p></caption><graphic xlink:href="pone.0017366.g006"/></fig><p>
<italic>Systemic inflammatory immune responses:</italic> Gluten-specific
IFN-&#x003b3;-producing PBMCs were measured by ELISpot before and after wheat
challenge (<xref ref-type="fig" rid="pone-0017366-g006">Figure 6B</xref>).
As expected, T cells secreting IFN-&#x003b3; in response to p57&#x02013;73 QE65
were absent prior to wheat challenge (data not shown), but were mobilised
into blood following the challenge. The frequency of IFN-&#x003b3; secreting T
cells specific for p57&#x02013;73 QE65 increased significantly only in the
control group (p&#x0200a;=&#x0200a;0.01), but the difference between
the groups was not significant.</p></sec><sec id="s3b2"><title>Secondary Outcomes</title><p>
<italic>Clinical response to wheat challenge &#x02014; Symptom scores:</italic>
Nine subjects (4 with hookworm and 5 controls) developed abdominal
discomfort, bloating and vomiting 1&#x02013;2 hours after the oral wheat
challenge. These symptoms resolved within 2&#x02013;4 hours (data not shown).
These symptoms did not recur despite continuation and completion of the five
day wheat challenge. There was no significant difference between the groups
during week 20 in level of pain intensity or episodes of pain, number or
urgency of bowel motions, vomiting, nausea bloating, headaches, lethargy or
well-being.</p><p>
<italic>Mucosal inflammatory response &#x02014; Duodenal histological
measurements:</italic> After the 5-day <italic>in vivo</italic> wheat
challenge, the total, CD3<sup>&#x0002b;</sup> and CD8<sup>&#x0002b;</sup> duodenal
IEL counts increased in both groups (<xref ref-type="table" rid="pone-0017366-t002">Table 2</xref>). The CD4<sup>&#x0002b;</sup> IEL
counts were not significantly affected by either <italic>in vivo</italic>
wheat challenge or hookworm infection. A robust but almost identical
decrease in the Vh&#x02236;Cd ratio after gluten was measured in the hookworm
and control groups (<xref ref-type="table" rid="pone-0017366-t002">Table
2</xref>).</p><table-wrap id="pone-0017366-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0017366.t002</object-id><label>Table 2</label><caption><title>Duodenal cellular responses following <italic>in vivo</italic>
gluten challenge.</title></caption><alternatives><graphic id="pone-0017366-t002-2" xlink:href="pone.0017366.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="2" align="left" rowspan="1">Control</td><td colspan="2" align="left" rowspan="1">Hookworm</td><td colspan="3" align="left" rowspan="1">p values</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Week 20</td><td align="left" rowspan="1" colspan="1">Week 21</td><td align="left" rowspan="1" colspan="1">Week 20</td><td align="left" rowspan="1" colspan="1">Week 21</td><td align="left" rowspan="1" colspan="1">Time</td><td align="left" rowspan="1" colspan="1">Group</td><td align="left" rowspan="1" colspan="1">Interaction</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Total IEL</td><td align="left" rowspan="1" colspan="1">30.5(14.8&#x02013;46.2)</td><td align="left" rowspan="1" colspan="1">52.55(32.5&#x02013;72.6)</td><td align="left" rowspan="1" colspan="1">26.4(19.4&#x02013;33.4)</td><td align="left" rowspan="1" colspan="1">43.5(32.7&#x02013;54.3)</td><td align="left" rowspan="1" colspan="1">
<bold>0.0037</bold>
</td><td align="left" rowspan="1" colspan="1">0.30</td><td align="left" rowspan="1" colspan="1">0.70</td></tr><tr><td align="left" rowspan="1" colspan="1">CD8&#x0002b; IEL</td><td align="left" rowspan="1" colspan="1">32.95(19.5&#x02013;46.4)</td><td align="left" rowspan="1" colspan="1">45.75(33.6&#x02013;57.9)</td><td align="left" rowspan="1" colspan="1">38.55(31.8&#x02013;45.3)</td><td align="left" rowspan="1" colspan="1">54.05(36.6&#x02013;71.5)</td><td align="left" rowspan="1" colspan="1">
<bold>0.019</bold>
</td><td align="left" rowspan="1" colspan="1">0.24</td><td align="left" rowspan="1" colspan="1">0.82</td></tr><tr><td align="left" rowspan="1" colspan="1">CD4<sup>&#x0002b;</sup> IEL</td><td align="left" rowspan="1" colspan="1">0.85(&#x02212;0.043&#x02013;1.74)</td><td align="left" rowspan="1" colspan="1">2.75(&#x02212;0.43&#x02013;5.93)</td><td align="left" rowspan="1" colspan="1">0.55(0.090&#x02013;1.01)</td><td align="left" rowspan="1" colspan="1">0.7(0.087&#x02013;1.31)</td><td align="left" rowspan="1" colspan="1">0.18</td><td align="left" rowspan="1" colspan="1">0.13</td><td align="left" rowspan="1" colspan="1">0.25</td></tr><tr><td align="left" rowspan="1" colspan="1">CD3<sup>&#x0002b;</sup> IEL</td><td align="left" rowspan="1" colspan="1">37.65(23.4&#x02013;51.9)</td><td align="left" rowspan="1" colspan="1">58.9(44.4&#x02013;73.4)</td><td align="left" rowspan="1" colspan="1">42.45(34.0&#x02013;50.9)</td><td align="left" rowspan="1" colspan="1">60(42&#x02013;78)</td><td align="left" rowspan="1" colspan="1">
<bold>0.0039</bold>
</td><td align="left" rowspan="1" colspan="1">0.64</td><td align="left" rowspan="1" colspan="1">0.77</td></tr><tr><td align="left" rowspan="1" colspan="1">Villus Height</td><td align="left" rowspan="1" colspan="1">40.44(32.9&#x02013;48.0)</td><td align="left" rowspan="1" colspan="1">28.23(21.8&#x02013;34.6)</td><td align="left" rowspan="1" colspan="1">38.27(34.6&#x02013;41.9)</td><td align="left" rowspan="1" colspan="1">28.43(19.6&#x02013;37.3)</td><td align="left" rowspan="1" colspan="1">
<bold>0.0009</bold>
</td><td align="left" rowspan="1" colspan="1">0.75</td><td align="left" rowspan="1" colspan="1">0.70</td></tr><tr><td align="left" rowspan="1" colspan="1">Crypt Depth</td><td align="left" rowspan="1" colspan="1">15.9(14.1&#x02013;17.8)</td><td align="left" rowspan="1" colspan="1">18.08(15.8&#x02013;20.3)</td><td align="left" rowspan="1" colspan="1">15.38(13.5&#x02013;17.3)</td><td align="left" rowspan="1" colspan="1">18.54(15.5&#x02013;21.6)</td><td align="left" rowspan="1" colspan="1">
<bold>0.014</bold>
</td><td align="left" rowspan="1" colspan="1">0.98</td><td align="left" rowspan="1" colspan="1">0.64</td></tr><tr><td align="left" rowspan="1" colspan="1">Vh/Cd ratio</td><td align="left" rowspan="1" colspan="1">2.669(2.0&#x02013;3.3)</td><td align="left" rowspan="1" colspan="1">1.644(1.2&#x02013;2.1)</td><td align="left" rowspan="1" colspan="1">2.575(2.1&#x02013;3.0)</td><td align="left" rowspan="1" colspan="1">1.683(1.0&#x02013;2.3)</td><td align="left" rowspan="1" colspan="1">
<bold>0.0006</bold>
</td><td align="left" rowspan="1" colspan="1">0.91</td><td align="left" rowspan="1" colspan="1">0.79</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt106"><label/><p>Levels were analyzed by two-way ANOVA. p values considered
significant are indicated in bold.</p></fn></table-wrap-foot></table-wrap></sec></sec></sec><sec id="s4"><title>Discussion</title><p>The &#x0201c;hygiene hypothesis&#x0201d; is a plausible explanation for the increasing
incidence of autoimmune and allergic diseases in affluent societies, but it has been
difficult to directly elucidate the mechanism by which infectious agents such as
nematodes alter disease-causing immune responses in humans. In common with many
other immune diseases, the prevalence of CD has risen dramatically. We propose that
chronic helminthiasis, such as hookworm infection, may be immunomodulatory and alter
pathogenic immune responses <italic>in vivo</italic>.</p><p>In this Phase 1b/2a trial, we have established an experimental model allowing us to
explore how hookworm infection alters the effects of gluten in CD. Chronic hookworm
infection can be reliably and safely established in subjects with well controlled
disease. Lacking precedent, the size of this demanding study was small. We observed
at best weak trends towards reduced numbers of gluten peptide-specific T cells in
blood and histological damage following wheat challenge in CD.</p><p>As has been reported in another trial, standard fecal microscopy is relatively
insensitive in light infection; a negative test does not exclude colonization <xref rid="pone.0017366-Blount1" ref-type="bibr">[29]</xref>. All patients
inoculated acquired adult hookworms in the intestine. The pathognomic findings of a
transient papular rash at the site of inoculation, together with the common
development of mild abdominal pain in the period soon after the initial inoculation
hampered attempts to blind the hookworm-infected participants and investigators. In
each control participant however, genuine confusion as to status was usual. It is
inherently difficult to mask the hallmark features of hookworm inoculation, just as
it is to mimic them. Rather than inoculating every participant and subsequently
treating the controls with an anthelminthic, we felt obliged to accept this
compromise. The occurrence of abdominal pain has implications when evaluating
hookworms as therapy in clinical trials, especially during the establishment phase
where symptom scores to measure outcomes may be confounded <xref rid="pone.0017366-Croese2" ref-type="bibr">[20]</xref>. Because infection with NA
typically persists for years <xref rid="pone.0017366-Palmer1" ref-type="bibr">[30]</xref>, <xref rid="pone.0017366-Beaver1" ref-type="bibr">[31]</xref>, the morbidity occurring during early infection should be
accounted for by undertaking studies after chronic infection is established.</p><p>The refusal of all participants in the active arm to take anthelminthic therapy after
completion of the trial was not unique to this study <xref rid="pone.0017366-Croese2" ref-type="bibr">[20]</xref>, <xref rid="pone.0017366-Feary2" ref-type="bibr">[32]</xref> and supports the contention that
chronic light hookworm infection does not compromise wellbeing, an argument
congruous with the trend in the improved lethargy score. Although it is well
recognized that heavy hookworm infection causes clinically significant blood loss
<xref rid="pone.0017366-Hotez1" ref-type="bibr">[15]</xref>, the
legitimate concern that experimental infection would cause anemia in patients
already predisposed with CD did not eventuate. As anticipated from a previous
experimental inoculation study utilising capsule endoscopy <xref rid="pone.0017366-Croese1" ref-type="bibr">[18]</xref>, the hookworm group acquired
peripheral and mucosal eosinophilia but the mucosa at week 20 was not obviously
damaged.</p><p>Following the epidemiological evidence of a causal association between the
disappearance of helminths from societies with advanced sanitary infrastructure and
the apparent rise in incidence of autoimmune and allergic diseases <xref rid="pone.0017366-Altmann1" ref-type="bibr">[3]</xref>, a number of
interventional clinical trials have been undertaken <xref rid="pone.0017366-Bager1" ref-type="bibr">[12]</xref>, <xref rid="pone.0017366-Croese2" ref-type="bibr">[20]</xref>, <xref rid="pone.0017366-Feary2" ref-type="bibr">[32]</xref>, <xref rid="pone.0017366-Summers3" ref-type="bibr">[33]</xref>, with inconsistent results.
The porcine whipworm, <italic>T. suis</italic>, has been reported as beneficial in
Crohn's disease and ulcerative colitis <xref rid="pone.0017366-Summers3" ref-type="bibr">[33]</xref>, both conditions which share
genetic traits with CD <xref rid="pone.0017366-Glas1" ref-type="bibr">[34]</xref>. However, a recently reported controlled trial using this
helminth in patients with allergic rhinitis demonstrated that while an immunological
response to whipworm was elicited, no therapeutic benefit was apparent <xref rid="pone.0017366-Bager1" ref-type="bibr">[12]</xref>. Similarly, in a
trial where NA infection was tested for an effect among patients with asthma, no
significant benefit from helminth infection was reported <xref rid="pone.0017366-Feary2" ref-type="bibr">[32]</xref>. While our experience from a
proof of concept study where patients with active Crohn's disease were infected
with hookworm suggested an early benefit, their wellbeing was reliant on
continuation of immunosuppressive therapies <xref rid="pone.0017366-Croese2" ref-type="bibr">[20]</xref>.</p><p>Our study establishes that hookworm infection on its own will not obviate the
necessity for a restricted diet in CD. However, this experimental human challenge
system appears to be a safe way of investigating the effect helminth parasites might
impact on immune pathology. The advantages are that it directly addresses the human
response, the disease process is not affected by the clinical imperative to use
immune modulating therapy, intestinal tissue as well as blood is available for
analyses and antigen stimulation testing can be effected both <italic>in
vivo</italic> and <italic>in vitro</italic>.</p></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0017366.s001"><label>Checklist S1</label><caption><p>CONSORT Checklist.</p><p>(PDF)</p></caption><media xlink:href="pone.0017366.s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0017366.s002"><label>Protocol S1</label><caption><p>Study Protocol.</p><p>(PDF)</p></caption><media xlink:href="pone.0017366.s002.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>The authors wish to gratefully acknowledge the valued contribution made by Dr Owen
Harris who agreed to be the clinical monitor for this trial. They also wish to
acknowledge the contribution made by Dr Linda Fletcher for assistance with specimen
handling.</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist. Envoi Specialist
Pathologists, Brisbane, QLD, Australia contributed to the processing and the
interpretation (Prof. Clouston) of the histological material, but neither the
organisation nor any employee has any commercial interest beyond this support
nor a competing interest. Envoi's involvement does not affect or alter the
authors' adherence to all the PLoS ONE policies on sharing data and
materials.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>The study was funded by the Broad Medical Research Program of The Broad
Foundation. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript. Prof. Andrew
Clouston is a principal of and clinical pathologist at Envoi Specialist
Pathologists, Brisbane, QLD, Australia, which processed tissue sections for
histological grading. Prof. Clouston contributed to the interpretation and
grading of the histology, and the preparation of the manuscript. Neither Prof.
Clouston nor Envoi Specialist Pathologists has any patent or financial interest
in the product of this clinical trial.</p></fn></fn-group><ref-list><title>References</title><ref id="pone.0017366-Bach1"><label>1</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bach</surname><given-names>JF</given-names></name></person-group>
<year>2002</year>
<article-title>The effect of infections on susceptibility to autoimmune and
allergic diseases.</article-title>
<source>The N Engl J Med</source>
<volume>347</volume>
<fpage>911</fpage>
<lpage>920</lpage>
<pub-id pub-id-type="pmid">12239261</pub-id></element-citation></ref><ref id="pone.0017366-Weinstock1"><label>2</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weinstock</surname><given-names>JV</given-names></name><name><surname>Elliott</surname><given-names>DE</given-names></name></person-group>
<year>2009</year>
<article-title>Helminths and the IBD hygiene hypothesis.</article-title>
<source>Inflamm Bowel Dis</source>
<volume>15</volume>
<fpage>128</fpage>
<lpage>133</lpage>
<pub-id pub-id-type="pmid">18680198</pub-id></element-citation></ref><ref id="pone.0017366-Altmann1"><label>3</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Altmann</surname><given-names>DM</given-names></name></person-group>
<year>2009</year>
<article-title>Review series on helminths, immune modulation and the hygiene
hypothesis: nematode coevolution with adaptive immunity, regulatory networks
and the growth of inflammatory diseases.</article-title>
<source>Immunology</source>
<volume>126</volume>
<fpage>1</fpage>
<lpage>2</lpage>
<pub-id pub-id-type="pmid">19120492</pub-id></element-citation></ref><ref id="pone.0017366-Jackson1"><label>4</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jackson</surname><given-names>JA</given-names></name><name><surname>Friberg</surname><given-names>IM</given-names></name><name><surname>Little</surname><given-names>S</given-names></name><name><surname>Bradley</surname><given-names>JE</given-names></name></person-group>
<year>2009</year>
<article-title>Review series on helminths, immune modulation and the hygiene
hypothesis: immunity against helminths and immunological phenomena in modern
human populations: coevolutionary legacies?</article-title>
<source>Immunology</source>
<volume>126</volume>
<fpage>18</fpage>
<lpage>27</lpage>
<pub-id pub-id-type="pmid">19120495</pub-id></element-citation></ref><ref id="pone.0017366-Fumagalli1"><label>5</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fumagalli</surname><given-names>M</given-names></name><name><surname>Pozzoli</surname><given-names>U</given-names></name><name><surname>Cagliani</surname><given-names>R</given-names></name><name><surname>Comi</surname><given-names>GP</given-names></name><name><surname>Riva</surname><given-names>S</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>Parasites represent a major selective force for interleukin genes
and shape the genetic predisposition to autoimmune
conditions.</article-title>
<source>J Exp Med</source>
<volume>206</volume>
<issue>6</issue>
<fpage>1395</fpage>
<lpage>1408</lpage>
<pub-id pub-id-type="pmid">19468064</pub-id></element-citation></ref><ref id="pone.0017366-Aoyama1"><label>6</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aoyama</surname><given-names>H</given-names></name><name><surname>Hirata</surname><given-names>T</given-names></name><name><surname>Sakugawa</surname><given-names>H</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Miyagi</surname><given-names>S</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>An inverse relationship between autoimmune liver diseases and
Strongyloides stercoralis infection.</article-title>
<source>Am J Trop Med Hyg</source>
<volume>76</volume>
<fpage>972</fpage>
<lpage>976</lpage>
<pub-id pub-id-type="pmid">17488925</pub-id></element-citation></ref><ref id="pone.0017366-Correale1"><label>7</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Correale</surname><given-names>J</given-names></name><name><surname>Farez</surname><given-names>M</given-names></name></person-group>
<year>2007</year>
<article-title>Association between parasite infection and immune responses in
multiple sclerosis.</article-title>
<source>Ann Neurol</source>
<volume>61</volume>
<fpage>97</fpage>
<lpage>108</lpage>
<pub-id pub-id-type="pmid">17230481</pub-id></element-citation></ref><ref id="pone.0017366-Elliott1"><label>8</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Elliott</surname><given-names>DE</given-names></name><name><surname>Weinstock</surname><given-names>JV</given-names></name></person-group>
<year>2009</year>
<article-title>Helminthic therapy: using worms to treat immune-mediated
disease.</article-title>
<source>Adv Exp Med Biol</source>
<volume>666</volume>
<fpage>157</fpage>
<lpage>166</lpage>
<pub-id pub-id-type="pmid">20054982</pub-id></element-citation></ref><ref id="pone.0017366-Ruyssers1"><label>9</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ruyssers</surname><given-names>NE</given-names></name><name><surname>De Winter</surname><given-names>BY</given-names></name><name><surname>De Man</surname><given-names>JG</given-names></name><name><surname>Ruyssers</surname><given-names>ND</given-names></name><name><surname>Van Gils</surname><given-names>AJ</given-names></name><etal/></person-group>
<year>2010</year>
<article-title>Schistosoma mansoni proteins attenuate gastrointestinal motility
disturbances during experimental colitis in mice.</article-title>
<source>World J Gastroenterol</source>
<volume>16</volume>
<fpage>703</fpage>
<lpage>712</lpage>
<pub-id pub-id-type="pmid">20135718</pub-id></element-citation></ref><ref id="pone.0017366-Musgrove1"><label>10</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Musgrove</surname><given-names>P</given-names></name><name><surname>Hotez</surname><given-names>PJ</given-names></name></person-group>
<year>2009</year>
<article-title>Turning neglected tropical diseases into forgotten
maladies.</article-title>
<source>Health Aff (Millwood)</source>
<volume>28</volume>
<fpage>1691</fpage>
<lpage>1706</lpage>
<pub-id pub-id-type="pmid">19887410</pub-id></element-citation></ref><ref id="pone.0017366-Feary1"><label>11</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Feary</surname><given-names>J</given-names></name><name><surname>Venn</surname><given-names>A</given-names></name><name><surname>Brown</surname><given-names>A</given-names></name><name><surname>Hooi</surname><given-names>D</given-names></name><name><surname>Falcone</surname><given-names>FH</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>Safety of hookworm infection in individuals with measurable
airway responsiveness: a randomized placebo-controlled feasibility
study.</article-title>
<source>Clin Exp Allergy</source>
<volume>39</volume>
<fpage>1060</fpage>
<lpage>1068</lpage>
<pub-id pub-id-type="pmid">19400893</pub-id></element-citation></ref><ref id="pone.0017366-Bager1"><label>12</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bager</surname><given-names>P</given-names></name><name><surname>Arnved</surname><given-names>J</given-names></name><name><surname>Ronborg</surname><given-names>S</given-names></name><name><surname>Wohlfahrt</surname><given-names>J</given-names></name><name><surname>Poulsen</surname><given-names>LK</given-names></name><etal/></person-group>
<year>2010</year>
<article-title>Trichuris suis ova therapy for allergic rhinitis: a randomized,
double-blind, placebo-controlled clinical trial.</article-title>
<source>J Allergy Clin Immunol</source>
<volume>125</volume>
<fpage>123</fpage>
<lpage>130</lpage>
<pub-id pub-id-type="pmid">19800680</pub-id></element-citation></ref><ref id="pone.0017366-Summers1"><label>13</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Summers</surname><given-names>RW</given-names></name><name><surname>Elliott</surname><given-names>DE</given-names></name><name><surname>Qadir</surname><given-names>K</given-names></name><name><surname>Urban</surname><given-names>JF</given-names><suffix>Jr</suffix></name><name><surname>Thompson</surname><given-names>R</given-names></name><etal/></person-group>
<year>2003</year>
<article-title>Trichuris suis seems to be safe and possibly effective in the
treatment of inflammatory bowel disease.</article-title>
<source>Am J Gastroenterol</source>
<volume>98</volume>
<fpage>2034</fpage>
<lpage>2041</lpage>
<pub-id pub-id-type="pmid">14499784</pub-id></element-citation></ref><ref id="pone.0017366-Summers2"><label>14</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Summers</surname><given-names>RW</given-names></name><name><surname>Elliott</surname><given-names>DE</given-names></name><name><surname>Urban</surname><given-names>JF</given-names><suffix>Jr</suffix></name><name><surname>Thompson</surname><given-names>RA</given-names></name><name><surname>Weinstock</surname><given-names>JV</given-names></name></person-group>
<year>2005</year>
<article-title>Trichuris suis therapy for active ulcerative colitis: a
randomized controlled trial.</article-title>
<source>Gastroenterology</source>
<volume>128</volume>
<fpage>825</fpage>
<lpage>832</lpage>
<pub-id pub-id-type="pmid">15825065</pub-id></element-citation></ref><ref id="pone.0017366-Hotez1"><label>15</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hotez</surname><given-names>PJ</given-names></name><name><surname>Brooker</surname><given-names>S</given-names></name><name><surname>Bethony</surname><given-names>JM</given-names></name><name><surname>Bottazzi</surname><given-names>ME</given-names></name><name><surname>Loukas</surname><given-names>A</given-names></name><etal/></person-group>
<year>2004</year>
<article-title>Hookworm infection.</article-title>
<source>N Engl J Med</source>
<volume>351</volume>
<fpage>799</fpage>
<lpage>807</lpage>
<pub-id pub-id-type="pmid">15317893</pub-id></element-citation></ref><ref id="pone.0017366-Maxwell1"><label>16</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maxwell</surname><given-names>C</given-names></name><name><surname>Hussain</surname><given-names>R</given-names></name><name><surname>Nutman</surname><given-names>TB</given-names></name><name><surname>Poindexter</surname><given-names>RW</given-names></name><name><surname>Little</surname><given-names>MD</given-names></name><etal/></person-group>
<year>1987</year>
<article-title>The clinical and immunologic responses of normal human volunteers
to low dose hookworm (Necator americanus) infection.</article-title>
<source>Am J Trop Med Hyg</source>
<volume>37</volume>
<fpage>126</fpage>
<lpage>134</lpage>
<pub-id pub-id-type="pmid">3605493</pub-id></element-citation></ref><ref id="pone.0017366-Wright1"><label>17</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wright</surname><given-names>V</given-names></name><name><surname>Bickle</surname><given-names>Q</given-names></name></person-group>
<year>2005</year>
<article-title>Immune responses following experimental human hookworm
infection.</article-title>
<source>Clin Exp Immunol</source>
<volume>142</volume>
<fpage>398</fpage>
<lpage>403</lpage>
<pub-id pub-id-type="pmid">16232230</pub-id></element-citation></ref><ref id="pone.0017366-Croese1"><label>18</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Croese</surname><given-names>J</given-names></name><name><surname>Wood</surname><given-names>MJ</given-names></name><name><surname>Melrose</surname><given-names>W</given-names></name><name><surname>Speare</surname><given-names>R</given-names></name></person-group>
<year>2006</year>
<article-title>Allergy controls the population density of Necator americanus in
the small intestine.</article-title>
<source>Gastroenterology</source>
<volume>131</volume>
<fpage>402</fpage>
<lpage>409</lpage>
<pub-id pub-id-type="pmid">16890593</pub-id></element-citation></ref><ref id="pone.0017366-Mortimer1"><label>19</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mortimer</surname><given-names>K</given-names></name><name><surname>Brown</surname><given-names>A</given-names></name><name><surname>Feary</surname><given-names>J</given-names></name><name><surname>Jagger</surname><given-names>C</given-names></name><name><surname>Lewis</surname><given-names>S</given-names></name><etal/></person-group>
<year>2006</year>
<article-title>Dose-ranging study for trials of therapeutic infection with
Necator americanus in humans.</article-title>
<source>Am J Trop Med Hyg</source>
<volume>75</volume>
<fpage>914</fpage>
<lpage>920</lpage>
<pub-id pub-id-type="pmid">17123987</pub-id></element-citation></ref><ref id="pone.0017366-Croese2"><label>20</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Croese</surname><given-names>J</given-names></name><name><surname>O'Neil</surname><given-names>J</given-names></name><name><surname>Masson</surname><given-names>J</given-names></name><name><surname>Cooke</surname><given-names>S</given-names></name><name><surname>Melrose</surname><given-names>W</given-names></name><etal/></person-group>
<year>2006</year>
<article-title>A proof of concept study establishing Necator americanus in
Crohn's patients and reservoir donors.</article-title>
<source>Gut</source>
<volume>55</volume>
<fpage>136</fpage>
<lpage>137</lpage>
<pub-id pub-id-type="pmid">16344586</pub-id></element-citation></ref><ref id="pone.0017366-Quinnell1"><label>21</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Quinnell</surname><given-names>RJ</given-names></name><name><surname>Bethony</surname><given-names>J</given-names></name><name><surname>Pritchard</surname><given-names>DI</given-names></name></person-group>
<year>2004</year>
<article-title>The immunoepidemiology of human hookworm
infection.</article-title>
<source>Parasite Immunol</source>
<volume>26</volume>
<fpage>443</fpage>
<lpage>454</lpage>
<pub-id pub-id-type="pmid">15771680</pub-id></element-citation></ref><ref id="pone.0017366-Leffler1"><label>22</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Leffler</surname><given-names>DA</given-names></name><name><surname>Dennis</surname><given-names>M</given-names></name><name><surname>Edwards George</surname><given-names>J</given-names></name><name><surname>Jamma</surname><given-names>S</given-names></name><name><surname>Cook</surname><given-names>EF</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>A validated disease-specific symptom index for adults with celiac
disease.</article-title>
<source>Clin Gastroenterol Hepatol</source>
<volume>7</volume>
<fpage>1328</fpage>
<lpage>1334</lpage>
<pub-id pub-id-type="pmid">19665584</pub-id></element-citation></ref><ref id="pone.0017366-Green1"><label>23</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Green</surname><given-names>PH</given-names></name><name><surname>Cellier</surname><given-names>C</given-names></name></person-group>
<year>2007</year>
<article-title>Celiac disease.</article-title>
<source>N Engl J Med</source>
<volume>357</volume>
<fpage>1731</fpage>
<lpage>1743</lpage>
<pub-id pub-id-type="pmid">17960014</pub-id></element-citation></ref><ref id="pone.0017366-Catassi1"><label>24</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Catassi</surname><given-names>C</given-names></name><name><surname>Fabiani</surname><given-names>E</given-names></name><name><surname>Iacono</surname><given-names>G</given-names></name><name><surname>D'Agate</surname><given-names>C</given-names></name><name><surname>Francavilla</surname><given-names>R</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>A prospective, double-blind, placebo-controlled trial to
establish a safe gluten threshold for patients with celiac
disease.</article-title>
<source>Am J Clin Nutr</source>
<volume>85</volume>
<fpage>160</fpage>
<lpage>166</lpage>
<pub-id pub-id-type="pmid">17209192</pub-id></element-citation></ref><ref id="pone.0017366-Marsh1"><label>25</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Marsh</surname><given-names>MN</given-names></name><name><surname>Crowe</surname><given-names>PT</given-names></name></person-group>
<year>1995</year>
<article-title>Morphology of the mucosal lesion in gluten
sensitivity.</article-title>
<source>Baillieres Clin Gastroenterol</source>
<volume>9</volume>
<fpage>273</fpage>
<lpage>293</lpage>
<pub-id pub-id-type="pmid">7549028</pub-id></element-citation></ref><ref id="pone.0017366-TyeDin1"><label>26</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tye-Din</surname><given-names>J</given-names></name><name><surname>Anderson</surname><given-names>R</given-names></name></person-group>
<year>2008</year>
<article-title>Immunopathogenesis of celiac disease.</article-title>
<source>Curr Gastroenterol Rep</source>
<volume>10</volume>
<fpage>458</fpage>
<lpage>465</lpage>
<pub-id pub-id-type="pmid">18799120</pub-id></element-citation></ref><ref id="pone.0017366-Anderson1"><label>27</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Anderson</surname><given-names>RP</given-names></name><name><surname>Degano</surname><given-names>P</given-names></name><name><surname>Godkin</surname><given-names>AJ</given-names></name><name><surname>Jewell</surname><given-names>DP</given-names></name><name><surname>Hill</surname><given-names>AV</given-names></name></person-group>
<year>2000</year>
<article-title>
<italic>In vivo</italic> antigen challenge in celiac disease
identifies a single transglutaminase-modified peptide as the dominant
A-gliadin T-cell epitope.</article-title>
<source>Nat Med</source>
<volume>6</volume>
<fpage>337</fpage>
<lpage>342</lpage>
<pub-id pub-id-type="pmid">10700238</pub-id></element-citation></ref><ref id="pone.0017366-Kagnoff1"><label>28</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kagnoff</surname><given-names>MF</given-names></name></person-group>
<year>2007</year>
<article-title>Celiac disease: pathogenesis of a model immunogenetic
disease.</article-title>
<source>J Clin Invest</source>
<volume>117</volume>
<fpage>41</fpage>
<lpage>49</lpage>
<pub-id pub-id-type="pmid">17200705</pub-id></element-citation></ref><ref id="pone.0017366-Blount1"><label>29</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Blount</surname><given-names>D</given-names></name><name><surname>Hooi</surname><given-names>D</given-names></name><name><surname>Feary</surname><given-names>J</given-names></name><name><surname>Venn</surname><given-names>A</given-names></name><name><surname>Telford</surname><given-names>G</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>Immunologic profiles of persons recruited for a randomized,
placebo-controlled clinical trial of hookworm infection.</article-title>
<source>Am J Trop Med Hyg</source>
<volume>81</volume>
<fpage>911</fpage>
<lpage>916</lpage>
<pub-id pub-id-type="pmid">19861631</pub-id></element-citation></ref><ref id="pone.0017366-Palmer1"><label>30</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Palmer</surname><given-names>ED</given-names></name></person-group>
<year>1955</year>
<article-title>Course of egg output over a 15 year period in a case of
experimentally induced necatoriasis americanus, in the absence of
hyperinfection.</article-title>
<source>Am J Trop Med Hyg</source>
<volume>4</volume>
<fpage>756</fpage>
<lpage>757</lpage>
<pub-id pub-id-type="pmid">13238732</pub-id></element-citation></ref><ref id="pone.0017366-Beaver1"><label>31</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Beaver</surname><given-names>PC</given-names></name></person-group>
<year>1988</year>
<article-title>Light, long-lasting Necator infection in a
volunteer.</article-title>
<source>Am J Trop Med Hyg</source>
<volume>39</volume>
<fpage>369</fpage>
<lpage>372</lpage>
<pub-id pub-id-type="pmid">3189697</pub-id></element-citation></ref><ref id="pone.0017366-Feary2"><label>32</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Feary</surname><given-names>JR</given-names></name><name><surname>Venn</surname><given-names>AJ</given-names></name><name><surname>Mortimer</surname><given-names>K</given-names></name><name><surname>Brown</surname><given-names>AP</given-names></name><name><surname>Hooi</surname><given-names>D</given-names></name><etal/></person-group>
<year>2010</year>
<article-title>Experimental hookworm infection: a randomized placebo-controlled
trial in asthma.</article-title>
<source>Clin Exp Allergy</source>
<volume>40</volume>
<fpage>299</fpage>
<lpage>306</lpage>
<pub-id pub-id-type="pmid">20030661</pub-id></element-citation></ref><ref id="pone.0017366-Summers3"><label>33</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Summers</surname><given-names>RW</given-names></name><name><surname>Elliott</surname><given-names>DE</given-names></name><name><surname>Urban</surname><given-names>JF</given-names><suffix>Jr</suffix></name><name><surname>Thompson</surname><given-names>R</given-names></name><name><surname>Weinstock</surname><given-names>JV</given-names></name></person-group>
<year>2005</year>
<article-title>Trichuris suis therapy in Crohn's disease.</article-title>
<source>Gut</source>
<volume>54</volume>
<fpage>87</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="pmid">15591509</pub-id></element-citation></ref><ref id="pone.0017366-Glas1"><label>34</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Glas</surname><given-names>J</given-names></name><name><surname>Stallhofer</surname><given-names>J</given-names></name><name><surname>Ripke</surname><given-names>S</given-names></name><name><surname>Wetzke</surname><given-names>M</given-names></name><name><surname>Pfennig</surname><given-names>S</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>Novel genetic risk markers for ulcerative colitis in the IL2/IL21
region are in epistasis with IL23R and suggest a common genetic background
for ulcerative colitis and celiac disease.</article-title>
<source>Am J Gastroenterol</source>
<volume>104</volume>
<fpage>1737</fpage>
<lpage>1744</lpage>
<pub-id pub-id-type="pmid">19455118</pub-id></element-citation></ref></ref-list></back></article>